전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved30 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
AntibodyLimited DatastaleRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Active
CGTLimited DatastaleGeneplus-Beijing Co. Ltd.Phase 2

DC-CIK (DC-CIK)

Renal Cell Carcinoma · Renal Neoplasma

#RenalNeoplasma#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 46Status Recruiting
AntibodyCurated CorestaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 40Status Discontinued
AntibodyLimited DatastaleSanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#monoclonal-antibody#ImmuneSystemDisorder+2
Trials 39Status Active
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
CGTLimited DatastaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 4Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD123 CAR NK cells (Anti-CD123 CAR NK cells)

AML (Acute Myeloid Leukemia); BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) · AML (Acute Myeloid Leukemia)

#AMLAcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

CAR-T cells Infusion chimeric antigen receptor T cells (CAR-T cells Infusion chimeric antigen receptor T cells)

Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

Auto CAR-T (Auto CAR-T)

Plasma Cell Tumors · Plasma Cell Tumors

#PlasmaCellTumors#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleProvidence Health & ServicesPhase 2

Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG, Bortezomib, Thymoglobulin, Rituximab, Gamimune N,, Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis)

Heart Transplantation · Heart Transplantation

#HeartTransplantation#Antibody#Phase2#monoclonal-antibody#Providence
Trials 1Status Discontinued
CGTLimited DatastaleThe General Hospital of Western…Phase 1

CAR 70-BCMA CAR-T (CAR 70-BCMA CAR-T)

Relapsed or Refractory Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 1

CAR BCMA-CD70-T cells (CAR BCMA-CD70-T cells)

High-risk Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

CAR-T cells Infusion (CAR-T cells Infusion)

Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →